Company / SG&A per Share
Astria Therapeutics, Inc. SG&A per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.61
FY2024
5-year range
$0.61 / $3.87
FY2020-FY2024
Trend
-28.1%
vs FY2023
Sector context
#153 of 210
Health Care
What the data says
At $0.61, Astria Therapeutics, Inc.'s sg&a per share ranks #58 of 210 in the Health Care sector. SG&A per Share has declined for 4 consecutive years, from $3.87 in FY2020 to $0.61 in FY2024.
Based on SEC 10-K filings.
0.61 in FY2024 with a 5-year CAGR of -7.5%.
Improved from $1.32 to $0.61 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -28.2%
- 5-Year CAGR
- -7.5%
- 10-Year CAGR
- -
Sector benchmark
#58 of 210 in Health CareTop 27% of 210This company $0.61 Sector average $40.75
▼
-98.5% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s sg&a per share has declined for 4 consecutive years.
- In FY2024, sg&a per share decreased 28.1% year-over-year.
- Ranks #153 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.61 | -28.1% |
| FY2023 | $0.85 | -35.2% |
| FY2022 | $1.32 | -20.7% |
| FY2021 | $1.66 | -57.2% |
| FY2020 | $3.87 | +327.7% |
| FY2019 | $0.91 | -50.9% |
| FY2018 | $1.85 | -55.1% |
| FY2017 | $4.11 | +560.0% |
| FY2016 | $0.62 | -42.0% |
| FY2015 | $1.07 | -92.4% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026